PE20090512A1 - Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53 - Google Patents

Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53

Info

Publication number
PE20090512A1
PE20090512A1 PE2008001310A PE2008001310A PE20090512A1 PE 20090512 A1 PE20090512 A1 PE 20090512A1 PE 2008001310 A PE2008001310 A PE 2008001310A PE 2008001310 A PE2008001310 A PE 2008001310A PE 20090512 A1 PE20090512 A1 PE 20090512A1
Authority
PE
Peru
Prior art keywords
mdm2
interaction
inhibitors
compound
phenylenediamines
Prior art date
Application number
PE2008001310A
Other languages
English (en)
Inventor
Alain Philippe Poncelet
Bruno Schoentjes
Virginie Sophie Poncelet
Pierre-Henri Storck
Carina Leys
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20090512A1 publication Critical patent/PE20090512A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA UN COMPUESTO DE FORMULA (I) EN FORMA DE N- OXIDO, UNA SAL DE ADICION, UNA FORMA ISOMERICA TAL COMO ENANTIOMERO S O R, Y SU FORMA POLIMORFICA QUE COMPRENDE PICOS DE DIFRACCION EN POSICION DOS- TETHA DE 6,4‘+-0,2‘, 12,8‘+-0,2‘, 15,2‘+-0,2‘ Y 17,3‘+-0,2‘. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCESO DE PREPARACION. DICHO COMPUESTO ES INHIBIDOR DE UNA INTERACCION ENTRE P53-MDM2 UTIL EN EL TRATAMIENTO DE TUMORES Y CANCER
PE2008001310A 2007-08-06 2008-08-06 Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53 PE20090512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113878 2007-08-06

Publications (1)

Publication Number Publication Date
PE20090512A1 true PE20090512A1 (es) 2009-04-29

Family

ID=38872012

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001310A PE20090512A1 (es) 2007-08-06 2008-08-06 Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53

Country Status (10)

Country Link
US (1) US8853406B2 (es)
EP (1) EP2185541B1 (es)
AR (1) AR067813A1 (es)
CL (1) CL2008002316A1 (es)
ES (1) ES2534899T3 (es)
PA (1) PA8792401A1 (es)
PE (1) PE20090512A1 (es)
TW (1) TW200922557A (es)
UY (1) UY31273A1 (es)
WO (1) WO2009019274A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8541442B2 (en) * 2009-02-04 2013-09-24 Janssen Pharmaceutica N.V. Indole derivatives as anticancer agents
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
KR102674902B1 (ko) 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
AR123492A1 (es) * 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO863197A0 (en) 1997-08-18 1997-09-11 Fujisawa Pharmaceutical Co., Ltd. Novel derivatives
US6309492B1 (en) 1998-09-16 2001-10-30 Marc A. Seidner Polymer fill coating for laminate or composite wood products and method of making same
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
AU1290700A (en) 1998-12-02 2000-06-19 Pfizer Products Inc. Methods and compositions for restoring conformational stability of a protein of the p53 family
AU1734401A (en) 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
US6835731B2 (en) 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
DE60222396T2 (de) 2001-03-29 2008-05-15 Eli Lilly And Co., Indianapolis N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
WO2003040402A2 (en) 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
PT1443937E (pt) 2001-11-13 2008-09-23 Ortho Mcneil Janssen Pharm 1,4-benzodiazepinas substituídas e as suas utilizações para o tratamento de cancro
BR0215157A (pt) 2001-12-18 2004-10-19 Hoffmann La Roche Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores
GB0215650D0 (en) 2002-07-05 2002-08-14 Cyclacel Ltd Bisarylsufonamide compounds
ATE474833T1 (de) * 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53

Also Published As

Publication number Publication date
CL2008002316A1 (es) 2009-07-17
TW200922557A (en) 2009-06-01
WO2009019274A1 (en) 2009-02-12
AR067813A1 (es) 2009-10-21
PA8792401A1 (es) 2009-03-31
EP2185541A1 (en) 2010-05-19
UY31273A1 (es) 2009-03-02
US8853406B2 (en) 2014-10-07
EP2185541B1 (en) 2015-01-28
US20110130418A1 (en) 2011-06-02
ES2534899T3 (es) 2015-04-30

Similar Documents

Publication Publication Date Title
PE20090512A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
MX2009002306A (es) Nuevos inhibidores de mdm2 de molecula pequeña y sus usos.
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
CU20090206A7 (es) Solución novedosa no-acuosa tópica de diclofenaco y proceso para su preparación
SG171682A1 (en) Iap bir domain binding compounds
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
LU92338I2 (fr) Enzalutamide et ses sels pharmaceutiquement acceptables (XTANDI)
ATE522518T1 (de) Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
MX2010004493A (es) Compuestos de tropano.
UA109417C2 (uk) ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
WO2006091646A3 (en) Small molecule inhibitors of mdm2 and uses thereof
EA200970856A1 (ru) Ингибиторы пути хеджхога
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
MX2012005507A (es) Antagonistas de espiro-oxindol de mdm2.
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2009005934A (es) Compuestos organicos.
JO2848B1 (en) Organic compounds
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
EA201070237A1 (ru) Четвертичные опиоидные карбоксамиды
BR112012026289A2 (pt) composto orgânico para uso no tratamento de câncer do fígado
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
TNSN07419A1 (en) Methods for treating drug resistant cancer
EP2132013A4 (en) THIN METAL NANODRESSES MANUFACTURED BY BIOTEMPLATING

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed